{"filings":[{"id":96791,"accession_number":"0001493152-26-018580","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neuraxis ups ATM offering to $11.5M after selling 1.125M shares under prior $6.27M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Apr 21, 2026, Neuraxis filed a prospectus supplement increasing the ATM offering cap to $11,500,000 from $6,270,000.","Between Aug 29, 2025 and Apr 20, 2026, the company sold 1,125,281 common shares under the original ATM agreement.","Sales continue through agent Craig-Hallum Capital Group under the existing effective S-3 registration statement (No. 333-283798).","Proceeds from any future sales will be used for general corporate purposes as determined by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96790,"accession_number":"0001493152-26-018376","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Neuraxis reports preliminary Q1 2026 net sales of $1.6M, up 77% YoY; operating loss of $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents ~$7.1M as of March 31, 2026.","Net sales ~$1.6M for Q1 2026, up 77% from ~$0.9M in Q1 2025.","Gross profit ~$1.4M for Q1 2026.","Operating loss ~$1.7M for Q1 2026.","Preliminary unaudited results; final figures may change materially."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1607883.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127655,"accession_number":"0001493152-25-019186","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.","This is the first FDA clearance or approval specifically addressing functional dyspepsia in adults.","Clearance based on RCTs and real-world evidence; FDA extrapolated pediatric data to adults.","Company increased ATM offering from $3.3M to $6.27M; no shares sold under prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127654,"accession_number":"0001493152-25-019136","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Neuraxis reports preliminary Q3 net sales $0.8M, operating loss $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited cash and equivalents of $4.4M as of September 30, 2025.","Q3 net sales approx. $0.8M, gross profit $0.7M, operating loss $2.1M.","Nine-month net sales $2.6M, up from $1.9M in the prior year period.","Preliminary figures subject to change upon completion of quarter-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2601155.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144434,"accession_number":"0001641172-25-026158","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuraxis enters $3.3M ATM offering agreement with Craig-Hallum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering of up to $3.3M of common stock at prevailing market prices.","Sales agent Craig-Hallum will receive 3% commission plus up to $50K in legal fees.","Shares sold under effective S-3 registration statement filed Dec 2024.","Agreement allows sales at Company's sole discretion with customary parameters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144433,"accession_number":"0001641172-25-017723","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","1.02","5.02","9.01"],"status":"ready","headline":"Neuraxis ends Masimo partnership on NSS-2 Bridge; pays $200K, forfeits future royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated License and Collaboration Agreement with Masimo Corp., effective July 1, 2025.","Neuraxis to pay Masimo $200,000 in two installments (Dec 2025 and Jun 2026) for trademarks, patents, and inventory.","Neuraxis will no longer receive any licensing payments or revenue from the NSS-2 Bridge device.","Adopted 2025 Employee Stock Purchase Plan, offering 100,000 shares at 15% discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162790,"accession_number":"0001641172-25-013632","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuraxis stockholders approve Series B conversion stock issuance; elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Votes to approve issuance of 20%+ of outstanding common stock upon conversion of Series B Preferred Stock passed with 4.1M for, 129K against, 1.1M broker non-votes.","All six director nominees elected: Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, Kristen Ferge, Dr. Gilad Aharon.","Ratification of auditor Rosenberg Rich Baker Berman, P.A. approved with 5.66M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162789,"accession_number":"0001641172-25-012698","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neuraxis posts investor presentation to website; no specific financial details disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation covering strategy, performance, and objectives posted to ir.neuraxis.com on May 23, 2025.","No financial figures, guidance, or material events were reported in the filing or exhibit.","The 8-K serves solely as a Regulation FD disclosure; full presentation content is not included.","Company remains an emerging growth company; no operational or leadership changes noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162788,"accession_number":"0001641172-25-011973","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neuraxis announces $5.0M registered direct offering of 1.54M shares at $3.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,538,461 shares at $3.25/share; gross proceeds ~$5.0M before fees.","Expected to close on May 22, 2025; net proceeds for working capital and general corporate purposes.","Craig-Hallum Capital Group acting as exclusive placement agent for the offering.","Shares offered under effective shelf registration statement (File No. 333-283798)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162787,"accession_number":"0001641172-25-011939","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Neuraxis settles litigation for $750k payable starting Jan 2026; raises ~$1M from warrant exercises","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settles two lawsuits (Physicians' Litigation and Medical Practice Entities' Litigation) for $750,000 total, payable in 12 equal monthly installments beginning January 2026.","Settlement includes mutual release of all claims among all parties, with no admission of liability.","Received approximately $1M in proceeds from warrant exercises, issuing 430,580 common shares; Series B Preferred converted into 342,016 common shares.","Shares were issued without restrictive legend under the company's effective S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180757,"accession_number":"0001493152-25-001323","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).","Cash balance as of Dec 31, 2024 was ~$3.7 million.","Insurance coverage expanded to ~45M lives, up from 4M a year ago.","FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.","Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":2685925.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197600,"accession_number":"0001493152-24-047623","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.","Dr. Aharon co-founded Rosalind Advisors and purchased $250,000 of Series B Convertible Preferred Stock in the transaction.","He has not yet been assigned to any board committee; director compensation is undetermined.","No family relationships with other directors or officers; no other material interests in related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197599,"accession_number":"0001493152-24-047196","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Neuraxis amends Series B Preferred terms: extends dividends, increases authorized shares, revises voting rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased authorized Series B Preferred shares from 4,000,000 to 5,000,000.","Extended 8.5% annual dividend right by 18 months, now through December 31, 2026.","Amended voting rights: each Series B share votes equal to common shares convertible at $3.80 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197598,"accession_number":"0001493152-24-046285","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Neuraxis raises ~$5M through Series B Convertible Preferred Stock to three investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,100,840 shares of Series B Preferred Stock at $2.38 stated value for aggregate $5M, closed Nov 13, 2024.","Preferred ranks senior to common, convertible at any time into common shares; proceeds for working capital.","Registration rights require filing resale statement within 30 days; 1% monthly late penalty up to 6% of subscription amount, plus 18% interest if unpaid.","Investor board nominee Gil Aharon to join Board effective Jan 1, 2025, as long as investor holds ≥5% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197597,"accession_number":"0001493152-24-044545","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $667K, +40% YoY; unit sales +50%.","Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.","Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.","Received CPT Category I code for PENFS effective Jan 1, 2026.","Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924760.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197596,"accession_number":"0001493152-24-041597","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Neuraxis cuts Flagstaff investment to $1.8M, raises $145k from new Series B preferred sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth Amendment reduces Flagstaff SPA total from $5M to $1.8M; $800k received, $1M due by Dec 31, 2024.","New SPAs with multiple investors for 60,924 Series B Preferred shares at $2.38/share, aggregate $145k.","Series B Preferred convertible into common at any time; dividend/liquidation rights expire June 30, 2025.","Proceeds from the new SPAs to be used for working capital and general corporate purposes.","Flagstaff SPA termination terms revised; automatic upon full payment or breach with cure through Jan 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213823,"accession_number":"0001493152-24-036212","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Neuraxis converts $4.94M of convertible notes into 2.07M Series B Preferred shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["$4,935,001.90 of Preferred Stock Notes automatically converted into 2,073,524 Series B Preferred shares at $2.38/share.","Conversion occurred on Sept 9, 2024 after stockholder approval on Aug 15, 2024 and filing of Certificate of Designation.","Shares issued to Flagstaff International and other accredited investors; exempt from registration under Section 4(a)(2).","Series B Preferred ranks senior to common stock on liquidation, convertible into common at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213822,"accession_number":"0001493152-24-033444","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Neuraxis shareholders approve expanded equity plan and blank check preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85%–99.99% votes for; quorum of 65.61% achieved.","Incentive plan amended to double share pool to 600K plus 5% annual evergreen through 2031.","Blank check preferred stock authorized (3.52M votes for).","Issuance of 20%+ of common on conversion of Series B preferred or notes approved (3.63M for).","Non-binding say-on-pay approved; frequency set at once every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213821,"accession_number":"0001493152-24-030873","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.","Net loss $2.9M, up 30.5% YoY; operating loss $2.2M, up 97.5%.","Covered lives grew to 22.5M from 4.5M a year ago; commitment from payer with 12M lives starting Oct 1.","Submitted RED device to FDA for clearance expected Q4 2024; submitted label expansion to ages 8-21.","Secured additional $3.0M funding in May; total committed financing $9.1M; cash $1.8M, short-term debt $4.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":1258135.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213820,"accession_number":"0001493152-24-026362","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeurAxis grants fully vested stock to three non-employee directors; initiates quarterly equity compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three non-employee directors (Ferge, Keyser, Watkins) granted fully vested shares for services through March 31, 2024.","Shares valued at $2.78 per share (closing price June 28, 2024); first issuance under 2022 Plan post-IPO.","Future quarterly grants: each director to receive $12,500 in stock per quarter, totaling $50,000 annual equity compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233042,"accession_number":"0001493152-24-021615","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Neuraxis raises $3M via convertible notes at 8.5% interest; warrants amended","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued ~$3M aggregate principal convertible notes to three institutional investors; 8.5% annual interest payable quarterly.","Notes mature June 21, 2025; convert into Series B Preferred at $2.38/share after stockholder approval and certificate filing.","Proceeds for working capital and corporate purposes; no dividends or payments to affiliates permitted.","Holders of >70% of outstanding 2023 warrants agreed to waive anti-dilution rights in connection with the note issuance.","Stockholder approval for Series B Preferred authorization not yet obtained; conversion delayed until approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233041,"accession_number":"0001493152-24-014829","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neuraxis COO Dan Clarence terminated; severance through Oct 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Dan Clarence employment terminated effective April 10, 2024.","Severance: salary continuation at $275,000/yr through Oct 10, 2024.","Company will also pay Mr. Clarence's COBRA premiums through Oct 10, 2025.","No replacement named; CEO Brian Carrico remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233040,"accession_number":"0001493152-24-014075","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.","Restating Q3 2023 financials: $3.7M understatement of net loss and APIC due to warrant liability misclassification.","Cash at Dec 31, 2023 only $78.6K; secured $6.1M in convertible notes ($1.5M funded by Mar 31, 2024).","Insured lives expanded to ~16M (up 300% YoY), targeting 50M by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251204,"accession_number":"0001493152-24-011761","cik":1933567,"company_name":"Neuraxis, INC","ticker":"NRXS","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Neuraxis increases Flagstaff financing to $5M, replaces preferred with convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment raises Flagstaff investment from $3M to $5M via convertible promissory note.","Note carries 8.5% interest, matures in 15 months, convertible into Series B Preferred at $2.38/share.","Company has received $400,000 to date; 13 additional monthly installments scheduled through March 2025.","Conversion contingent on stockholder approval of Series B Preferred authorization, targeted by Sept 30, 2024.","Proceeds restricted to working capital and general corporate purposes; no dividends or affiliate payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90653843.3718121,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}